Related Experiment Video
Updated: Sep 21, 2025

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma
Yan Wang1, Peng Zhao1, Lili Wang1
1Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objective:
This study aimed to investigate the clinicopathological and molecular characteristics of ELOC(TCEB1)-mutant renal cell carcinoma.
Methods:
Sanger sequencing was used to assess 32 cases originally diagnosed as clear cell renal cell carcinoma with CK7 positive and/or fibromyomatous stroma. Of these, 4 patients with ELOC(TCEB1) gene mutation were screened, and their clinicopathological data were collected for histomorphological observation, immunohistochemical staining, and follow-up, and relevant pieces of literature were reviewed.
Results:
The 4 patients with ELOC(TCEB1) mutations were all males and aged between 57 and 64 years (median age: 59 years old). The tumor was located in the renal cortex, with a diameter of 2-3.5 cm. The cross-section was grayish-yellow and grayish brown, solid and nodular, and clearly demarcated from the surrounding tissues. Of the 4 patients, 3 harbored a thick fibrous pseudocapsule rich in smooth muscle and were separated from the surrounding normal renal tissue, and 2 of them showed focal invasion into the pseudocapsule, whereas 1 patient had no capsule but had focal invasion into the surrounding renal parenchyma. The tumor tissues mainly exhibited elongated or branched aciniform or tubular structures, commonly accompanied by interspersed small cystic and focal clustered short papillary structures. The cytoplasm of the tumor cells was rich and lightly stained, and the nuclear grading ranged from 1 to 2. All patients showed loose edema in the stroma, and 2 patients showed a small number of interspersed smooth muscle bundles. All 4 patients showed EMA, CA9, AMACR, and TCEB1 expression, and TCEB1 was mainly located in the nucleus. Vimentin, CK7, and CD10 expressions were observed in most cases; CD117, TFE3, HMB45, and melanA were not expressed in all tumors; the expression rate of Ki67 was 3%- 8%. All 4 patients had a point mutation in ELOC(TCEB1) Y79C. The patients were followed up for 24-93 months (mean 49 months), and all of them survived to date without recurrence or metastasis.
Conclusion:
ELOC(TCEB1)-mutant renal cell carcinoma is a rare type of renal cell carcinoma, which tends to occur in middle-aged and elderly men. The main characteristics of this tumor are the branching alveolar or tubular structure with clustered short papillae, presence of fibromyomatous stroma, and the expression of CK7, CA9, CD10, and AMACR. Positive TCEB1 nuclear staining may be an important marker and the Sanger sequencing method is helpful for the diagnosis of this type of RCC. Most patients harbor tumors exhibiting low nuclear grade and inert clinical behavior, and a few tumors exhibit high nuclear grade and aggressive characteristics.
Insights
This study identifies ELOC(TCEB1)-mutant renal cell carcinoma (RCC) as a rare cancer primarily affecting middle-aged men. These tumors often show specific structural and molecular features, and typically have an inert clinical behavior.
Area of Science:
- Urology
- Oncology
- Molecular Pathology
Background:
- Renal cell carcinoma (RCC) encompasses diverse subtypes with varying clinical behaviors.
- Identifying novel genetic drivers and their associated clinicopathological features is crucial for accurate diagnosis and management.
- ELOC(TCEB1) mutations represent a rare but distinct molecular subtype of RCC.
Purpose of the Study:
- To investigate the clinicopathological and molecular characteristics of ELOC(TCEB1)-mutant renal cell carcinoma.
- To identify diagnostic markers and understand the clinical behavior of this rare RCC subtype.
Main Methods:
- Sanger sequencing was employed to screen 32 cases of clear cell RCC with specific histological features.
- Four patients with confirmed ELOC(TCEB1) gene mutations underwent detailed clinicopathological analysis.
- Histomorphological observation, immunohistochemical staining, and literature review were performed.
Main Results:
- The 4 identified patients were males aged 57-64 years, with tumors located in the renal cortex.
- Histological findings included branching alveolar/tubular structures, fibromyomatous stroma, and positive expression of EMA, CA9, AMACR, and nuclear TCEB1.
- All patients had the ELOC(TCEB1) Y79C mutation, showed low nuclear grade, and had no recurrence or metastasis during a mean 49-month follow-up.
Conclusions:
- ELOC(TCEB1)-mutant RCC is a rare entity in middle-aged to elderly men, characterized by specific histological and molecular profiles.
- Positive TCEB1 nuclear staining and expression of CK7, CA9, CD10, and AMACR are key diagnostic indicators.
- This subtype generally exhibits an inert clinical behavior with a favorable prognosis, though some cases may present aggressive characteristics.

